A New Era of Generative AI for Everyone

Since the release of ChatGPT in 2022, the world has become increasingly exposed to the transformative potential of AI. This report by Criticaleye Partner Accenture explores the history of AI, while also looking to the future and how the commercial world can embrace Generative AI.

Key takeaways include:

  • Accenture found 40 percent of all working hours can be impacted by LLMs like Chat GPT.
  • 97 percent of global executives agree AI foundation models will enable connections across data types, revolutionising where and how AI is used.
  • Nearly 6 in 10 organisations plan to use ChatGPT for learning purposes and over half are planning pilot cases in 2023.




Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Click here to download this insight
Talent-centered Design: A Blu...

In this report, Criticaleye’s CEO Retreat 2024 Partner Eightfold AI discusses the need for businesses to fundamentally rethink how they manage talent ahead of a massive skills-based shift. The report also argues t...

Click here to download this insight
Lean Operating Models Thought...

Traditional thinking on corporate operating models is evolving. In this report, Criticaleye’s Advisory Partners, AlixPartners, discusses how many companies are revaluating their operating models and driving greate...

Click here to download this insight
Riding the Growth Wave in Asi...

Speakers at Criticaleye's Asia Leadership Retreat discuss why Asia remains the engine of global growth despite a slowdown. Businesses need to navigate cost pressures, talent, leadership and the changing financial la...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 1,794




E.ON UK Redwood Bank Lightsource bp NATS AlixPartners Amazon UK Drax Group plc LDC Eightfold AI Concentrix London Stock Exchange Robert Walters Google Royal London Group Veolia Water Technologies Bunzl plc Workday Accenture Eton Bridge Partners Tullow Oil plc Mayborn Group Salesforce Legal & General Investment Management GlaxoSmithKline plc